Background
Acral lentiginous melanoma (ALM) is a rare melanoma subtype found on the palms, soles and nailbeds. ALM is poorly responsive to immune checkpoint blockade and outcomes are poor for patients with advanced or metastatic disease. As such, novel treatment approaches are needed.